RFK Jr. vaccine comments bode well for GeoVax, says Roth Capital

Roth Capital analyst Jonathan Aschoff reiterated a Buy rating and $20 price target on GeoVax Labs (GOVX) after U.S. HHS Secretary Robert F. Kennedy Jr. told CBS News that monovalent vaccines do not work against respiratory viruses given the high viral mutation rates, and that the FDA is now prioritizing polyvalent vaccines against respiratory viruses. This view bodes well for GeoVax’s polyvalent COVID-19 vaccine GEO-CM04S1, which was awarded a large BARDA contract to fund a 10,000-subject Phase 2 trial, the analyst tells investors in a research note. The firm noted that GEO-CM04S1 is already outperforming mRNA COVID vaccines in a smaller Phase 2 trial.